<?xml version="1.0" encoding="UTF-8"?>
<p id="p0195">More than 470 million people globally are currently infected with hookworm, which causes anemia, malnutrition, physical and developmental delays, and substantial productivity losses 
 <xref rid="b0260" ref-type="bibr">[52]</xref>, 
 <xref rid="b0265" ref-type="bibr">[53]</xref>. In a Phase 1 trial, a human hookworm vaccine has been found to be safe, well tolerated, and immunogenic 
 <xref rid="b0270" ref-type="bibr">[54]</xref>. A Phase 2 trial is underway using a controlled human hookworm infection model (NCT03172975). In parallel, market research and financial modeling of costs and benefits are being conducted to develop an integrated business case for hookworm vaccines.
</p>
